China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its human diploid rabies vaccine. This marks a significant step forward in the development of more effective rabies prevention measures.
Vaccine Features and Advantages
The updated human diploid rabies vaccine boasts ultra-high efficiency and cost-effectiveness. Animal experiments have demonstrated that the vaccine can induce high levels of protective antibodies post-immunization. Notably, its efficacy is significantly superior to that of the currently marketed human diploid rabies vaccine when administered at the same dosage.
Clinical Trial Outlook
The initiation of the clinical study represents a crucial milestone for AIM Vaccine. The trial will evaluate the safety and immunogenicity of the vaccine in human subjects, paving the way for its potential market approval and widespread use in rabies prevention.-Fineline Info & Tech
Leave a Reply